Carregant...
Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation
Paclitaxel is a chemotherapeutic drug commonly used to treat different types of cancer. In addition to its antitumor effect, paclitaxel is also known to promote Toll-like receptor (TLR) 4-dependent inflammatory responses, which may lower its chemotherapeutic efficacy. However, it remains unclear whe...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6532018/ https://ncbi.nlm.nih.gov/pubmed/31156650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.01108 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|